Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

Inclusion Criteria: 1. Patients who have a diagnosis of pediatric or adult SLE according to the ACR 1997 revised criteria for ≥ 24 weeks prior to signing the ICF 2. To be eligible a patient must have SLEDAI-2K ≥ 6 points and "Clinical" SLEDAI-2K score ≥4 points at screening 3. BILAG2004 with at least 1 of the following: 1. BILAG2004 level A disease in ≥ 1 organ system 2. BILAG2004 level B disease in ≥ 2 organ systems 4. Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 VAS at Screening 5. Antinuclear antibody, and/or Anti-dsDNA and/oranti-Smith positive at Screening, 6. Must be on stable background standard therapy with DMARD, glucocorticoids or anti-malarials alone or in combinations. Exclusion Criteria: 7. Active severe or unstable neuropsychiatric SLE 8. Active severe SLE-driven renal disease 9. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF. 10. History of recurrent infection requiring hospitalization and IV antibiotics (eg, 3 or more of the same type of infection over the previous 52 weeks). 11. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the patient to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at Screening. 12. At Screening, confirmed positive test for hepatitis B serology and positive test for hepatitis C antibody 13. Any severe case herpes zoster infection at any time prior to Week 0 (Day 1), 14. Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization. 15. History of cancer, apart from: 1. Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥ 3 months prior to Week 0 (Day 1) 2. Cervical cancer in situ treated with apparent success with curative therapy ≥ 1 year prior to Week 0 (Day 1).